Abstract
Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study,
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have